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Abstract: Glycolysis, hypoxia, and proliferation are important factors in the tumor 
microenvironment contributing to treatment-resistant aggressiveness. Imaging these factors 
using combined functional positron emission tomography and computed tomography can 
potentially guide diagnosis and management of cancer patients. A dog with fibrosarcoma 
was imaged using 18F-FDG, 64Cu-ATSM, and 18F-FLT before, during, and after 10 fractions 
of 4.5 Gy radiotherapy. Uptake of all tracers decreased during treatment. Fluctuations in 
18F-FDG and 18F-FLT PET uptakes and a heterogeneous spatial distribution of the three 
tracers were seen. Tracer distributions partially overlapped. It appears that each tracer 
provides distinct information about tumor heterogeneity and treatment response. 
OPEN ACCESS
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1. Case Presentation 
A nine-year-old spayed, female, mixed-breed dog weighing 25 kg was referred to the  
oncology service at the University Hospital for Companion Animals, Department of Veterinary Clinical 
and Animal Sciences, University of Copenhagen, Denmark, with a suspected bone tumor in the 
proximal left tibia. The initial oncological work-up showed normal blood profiles and no evidence of 
metastases on three-view thoracic radiography or on fine needle aspirate from the left popliteal lymph 
node. Investigations also included CT and bone biopsies. The left proximal tibia showed both 
radiolucent and radiopaque areas, with most pronounced changes being found in the midplane and 
laterally. The lateral fabella showed irregular contours. There was no evidence of involvement of the 
stifle joint or on the thoracic CT of distant metastasis. Histopathology findings included infiltration of 
the marrow spaces by collagen and proliferating spindle cells, some of which showed minimal atypia 
and rare mitoses. Most sections showed no significant mitotic activity or atypia. Sarcoma was given as a 
histopathological diagnosis with a comment that the growth pattern and morphology was most 
consistent with a fibrosarcoma. 
Curative intent left hind limb amputation was recommended but declined. Radiotherapy (10 fractions 
of 4.5 Gy) was then offered, and as part of on-going research of PET tracers in cancer patients, it was 
possible to also offer PET/CT scan sequences for staging purposes and to monitor therapeutic response. 
The Ethics and Administrative Committee at the Department of Veterinary Clinical and Animal Sciences, 
Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, approved the pilot 
study protocol and owners provided written consent. 
2. PET/CT Imaging during Radiotherapy—Methods 
PET/CT scans with the glucose analogue, 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG); the cell 
proliferation PET tracer 3′-deoxy-3′-[18F]fluorothymidine (18F-FLT) [1,2]; and one promising hypoxia 
PET tracer 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) (64Cu-ATSM) [3,4] were performed on 
consecutive days one week prior to the first radiotherapy fraction, after five and 10 fractions of 
radiotherapy, and finally at 10 weeks after the end of treatment. 
The initial 18F-FDG PET/CT scan data was used for the radiotherapy plan. The gross tumor volume 
(GTV) was delineated on the CT by cooperation between a veterinarian and an experienced 
radiologist. Furthermore, a specialist in nuclear medicine helped in incorporating the evaluation of the 
18F-FDG PET in the GTV. 
All scans were performed on the same combined PET/CT scanner (Biograph40, Siemens, Munich, 
Germany) consisting of a 40-slice CT scanner and a high-resolution PET scanner. CT parameters were: 
120 kV, 170 mAs, pitch 1.2, collimation 24 × 1.2 mm, slice thickness 3.0 mm, and a B30 kernel. PET 
scans were acquired using a three-dimensional (3D) acquisition mode and True X reconstruction (point 
spread function, three iterations, 21 subsets, Syngo MI. PET/CT 2008A, Siemens, Munich, Germany) 
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and smoothed using a Gaussian filter having a full width at half maximum of 2 mm, and a matrix size 
of 336 × 336. 
Radiotherapy was administered using a linear accelerator (Novalis Tx™, Varian Medical Systems, 
Inc., Palo Alto, CA, USA). Six MV photons were given as a conformal 3D field technique. ExacTrac 
X-ray 6D (BrainLab, Feldkirchen, Germany) and cone beam CT were used to ensure precise and 
uniform positioning. 
The canine patient fasted for at least 12 h prior to all PET/CT scans and radiotherapy. Anesthesia during 
the procedures was induced with propofol (4 mg/kg, B. Braun Medical A/S, Frederiksberg, Denmark) 
after pre-medication with methadone (0.2–0.3 mg/kg i.m., Comfortan Vet 10 mg/mL, Dechra Veterinary 
Products A/S, Uldum, Denmark). Anesthesia was maintained using the continuous rate infusion of 
propofol (15–25 mg/kg/h) with 100% oxygen via an endo-tracheal tube. Heart rate, oxygen saturation, 
blood pressure, and CO2 concentrations were monitored throughout the anesthesia. During 
radiotherapy and PET/CT scans, the canine patient was positioned in a vacuum-fixed pillow to achieve 
precise and uniform positioning. Isocentric lasers and markers of copper wire were used to re-establish 
the correct patient position between individual scans and treatments. 
Before each 18F-FDG PET/CT scan, blood glucose measurements confirmed normal blood glucose 
levels. 18F-FDG from daily routine productions for clinical use and 18F-FLT produced as previously 
described [5] were produced at the Cyclotron Unit, Department of Clinical Physiology, Nuclear 
Medicine and PET, Copenhagen University Hospital, Denmark. 64Cu-ATSM was purchased from 
Hevesy Laboratory, DTU Campus Risø, Denmark. 
All tracers were injected as an intravenous bolus of approximately 7.2 MBq/kg with slight 
variations between tracers and scans. 18F-FDG and 18F-FLT were injected approximately 1 h (range 
56–95 min, median 69.5 min for 18F-FDG; range 60–86 min, median 76 min for 18F-FLT) prior  
to PET/CT scanning while 64Cu-ATSM was administered about 6.5 h (range 381–422 min, median  
406.5 min) prior to scanning. Both 18F-FDG and 18F-FLT PET/CT scans were performed as 10-min  
single-field-of-view static scans of the tumor area, while 64Cu-ATSM PET/CT scans were executed as  
20-min single-field-of-view scans. The first 18F-FDG PET/CT scan prior to radiotherapy planning 
furthermore included a 2-min five-fields-of-view full body PET scan to evaluate for metastasis. No 
metastases were found on the combined 18F-FDG PET/CT images. 
Images from the same scan series were manually co-registered according to the CT images. PET uptake 
was quantified using the standardized uptake value (SUV), which is a unitless semi-quantitative 
measure that accounts for the injected dose and the body weight [6,7]: 
SUV = Activity in tumor region (kBq/mL)/(Injected tracer activity (MBq)/body weight (kg)) (1)
Using the 18F-FDG PET/CT scan and 3D iso-contouring in TrueD (Syngo, Multi Modality Workplace 
VE40A, Siemens, Munich, Germany), a tumor volume defined by a SUV cut-off on 2.5 (18F-FDG 
SUV 2.5 volume) was delineated for each scan series (meaning the iso-contour-selected region where 
the 18F-FDG PET uptake is 2.5 SUV). These iso-contoured regions were applied as volumes of interest 
(VOIs) to the corresponding 64Cu-ATSM and 18F-FLT PET/CT images. Tumor maximum and mean 
SUVs (SUVmax and SUVmean) of all tracers were subsequently determined in the 18F-FDG SUV  
2.5 volumes/VOIs. Furthermore, a SUVmax-region defined as 90% of the maximum SUV was 
delineated for each tracer and scan. 
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The SUV cut-off on 2.5 was chosen since it has been used to discern between benign and malignant 
lesions when evaluating, for instance, lung and adrenal masses [8,9]. Additionally, in soft tissue lesions, 
18F-FDG PET is good at differentiating between benign and malignant [10]. Furthermore, in studies of 
Ewing sarcomas and extremity osteosarcomas, a 18F-FDG SUV value under 2.5 during scanning after 
neoadjuvant chemotherapy was predictive of progression-free survival [11,12]. 
3. Results and Outcome 
Tumor uptake of 64Cu-ATSM decreased continuously within the volume defined by 18F-FDG SUV 2.5 
during and after the course of radiotherapy, resulting in the reduction of 64Cu-ATSM SUVmax of >60% 
from the pre-treatment to the 10-week post-treatment scan (Figure 1). The same order of reduction 
from the pre-treatment to the 10-week post-radiotherapy scans was also found for 18F-FDG SUVmax 
and 18F-FLT SUVmax, though their uptake displayed fluctuations during radiotherapy (Figure 1). 
Furthermore, it was seen that 18F-FLT and 64Cu-ATSM might add information not available from  
18F-FDG PET/CT alone, since the SUVmax-regions of these two tracers were not co-localized with the 
18F-FDG SUV 2.5 volume (Figure 2). However, the scan at the end of radiotherapy showed a  
co-localized region of 18F-FLT and 18F-FDG uptake (Figure 1, column 3). 
 
Figure 1. PET/CT images of the tumor area in the left proximal tibia, transverse plane. 
Both uptake magnitude and distribution are different between the three tracers. Column 1: 
Before radiotherapy; Column 2: After 22.5 Gy of radiotherapy; Column 3: After 45 Gy of 
radiotherapy (at completion of radiotherapy); Column 4: 10 weeks after completing 
radiotherapy. Row A: 18F-FDG PET/CT; Row B: 18F-FLT PET/CT; Row C: 64Cu-ATSM 
PET/CT 6.5 h after intravenous injection. Pink angular lines demarcate 3D iso-contouring 
lines for the tumor volume of interest (VOI) defined by a standardized uptake value (SUV) 
cut-off at 2.5 for 18F-FDG (18F-FDG SUV 2.5 volume). First delineated on the 18F-FDG 
PET/CT images, these VOIs were subsequently applied to the corresponding 18F-FLT and 
64Cu-ATSM PET/CT images. The maximum and mean SUV values for the respective 
tracers in these VOIs/18F-FDG SUV 2.5 volumes are given in orange text. 18F-FDG 
PET/CT images are in window levels of SUV 0–6, while 18F-FLT and 64Cu-ATSM 
PET/CT images are in window levels of SUV 0–3 as also indicated by the color scale bars. 
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Figure 2. PET/CT images of the tumor area in the left proximal tibia, sagittal plane,  
10 weeks after completion of radiotherapy. The SUVmax-region for 18F-FLT (left picture) 
and 64Cu-ATSM (right picture) are localized outside the 18F-FDG SUV 2.5 volume. 
Orange rectangles demarcate 3D iso-contouring lines for the tumor volume of interest 
(VOI) defined by a standardized uptake value (SUV) cut-off at 2.5 for 18F-FDG (18F-FDG 
SUV 2.5 volume). The maximum and mean SUV values for the respective tracers in this 
VOI are given in orange text. The yellow rectangle demarcates 3D iso-contouring lines for 
the 18F-FLT SUVmax region. This is a region defined by 90% of the maximum SUV for  
18F-FLT in the tumor area. The maximum and mean SUV values for 18F-FLT uptake in this 
SUVmax-region are given in yellow text. The green rectangle demarcates 3D iso-contouring 
lines for the 64Cu-ATSM SUVmax region. This is a region defined by 90% of the maximum 
SUV for 64Cu-ATSM in the tumor area. The maximum and mean SUV values for  
64Cu-ATSM uptake in this 64Cu-ATSM SUVmax region are given in green text. 
The hypo-fractionated radiotherapy was well tolerated, the formation of an acute superficial moist 
dermatitis in the radiation field being the only sign of acute radiotherapy injuries. During and  
post-treatment, the canine patient showed varying but reduced degrees of lameness on the left hind 
limb. Lameness commenced after the fourth radiotherapy fraction, but decreased in the third week 
post-radiotherapy. Lameness increased again approximately five weeks post-radiotherapy, but could be 
controlled therapeutically, and about three months post-radiotherapy, the lameness was mild and 
intermittent, but there was still soreness at full extension of the left stifle joint. Lameness was first 
managed using firocoxib (Previcox 227 mg, Merial Norden A/S, Hørsholm, Denmark) initiated at 
initial presentation, but due to renal complication, this was withdrawn 4.5 months post-radiotherapy, 
leading to increasing degrees of lameness and pain. Physiotherapy twice weekly and, later, daily pain 
treatment with meloxicam (Metacam 1.5 mg/mL; Boehringer Ingelheim DK A/S, Copenhagen, 
Denmark, 0.1 mg/kg) made the canine patient improve. At seven months post-radiotherapy, there was  
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an acute deterioration with an acute lameness. A pathological tibial fracture was diagnosed and acute 
left hind limb amputation was recommended, but the owners decided to euthanize the canine patient. 
4. Discussion 
To the authors’ knowledge, this pilot study is one of the first to illustrate the simultaneous use of 
three different PET/CT tracers for non-invasive functional imaging of molecular changes in a canine 
cancer patient before, during, and after radiotherapy. 18F-FDG, 18F-FLT, and 64Cu-ATSM PET uptakes 
decreased initially during treatment, and from the pre-treatment scan to the post-treatment scan 10 weeks 
after completing therapy. The decrease in 64Cu-ATSM PET uptake was continuous during and after 
radiotherapy, indicating either tumor reoxygenation in areas of preserved 18F-FDG uptake signifying 
viable tumor tissue or necrosis, or non-functional tumor tissue in areas of reduced 18F-FDG uptake. 
The 18F-FDG and 18F-FLT PET uptakes showed some fluctuations during treatment. These variations 
in image signals may be a result of the differences in latency from tracer injection to imaging between 
the different scan series. However, the fluctuations in 18F-FLT PET uptakes may also indicate accelerated 
repopulation during therapy, while tissue remodeling and inflammation may explain the fluctuations in 
18F-FDG PET uptakes. This is due to the fact that 18F-FDG as a marker of glycolytic activity is not 
tumor-specific, but is also taken up by, for instance, macrophages during inflammation [13]. 
Inflammation during tissue remodeling may also account for the reduced but continued uptake of  
18F-FDG 10 weeks after completing therapy, even though incomplete tumor control cannot be ruled out. 
The co-localization and focal increase in 18F-FDG and 18F-FLT seen at scanning after the end of 
radiotherapy (Figure 1, column 3) might indicate that clones of cancer cells are repopulating the tumor 
area after the end of radiotherapy. As the image signal for both 18F-FDG and 18F-FLT is decreased at 
scanning 10 weeks after the end of therapy, perhaps an evaluation of the radiotherapy response in 
canine soft tissue sarcomas should not be done directly after completion of radiotherapy, but rather 
after waiting for some weeks. 
The visual interpretation of the scan images revealed a heterogeneous spatial distribution of the three 
tracers, which to some extent was overlapping, though not identical. This indicates that additional 
information about tumor heterogeneity and treatment response is gained through multi-tracer imaging. 
The use of multiple tracers may also be beneficial for individualized treatment planning and to predict 
outcome, since more aspects of the tumor phenotype are elucidated. This is illustrated in a recent study 
which showed that 64Cu-ATSM and 18F-FDG provide different biological information to be taken into 
account when using dose painting for radiotherapy planning [14]. With dose painting, a non-uniform 
radiation dose distribution is prescribed to the target volume based on information from, for instance, 
PET scans on tumor areas that might be resistant and thus require a higher dose [15]. The 
aforementioned study focused on dose painting of hypoxic areas [14], since tumor hypoxia has an 
essential impact on the molecular mechanisms in solid cancers by up-regulating multiple genes 
resulting in an aggressive phenotype and treatment resistance [16]. Though targeting hypoxic tumor 
areas is of great interest in the field of radiotherapy planning, other phenotypically distinct tumor areas 
such as highly proliferative areas delineated by 18F-FLT PET may also be worth attending in future 
radiotherapy planning research. 
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Until recently, guidelines for evaluating solid tumors’ responses to treatment relied on anatomical 
imaging techniques such as CT and MRI (RECIST) [17,18]. Since 18F-FDG PET/CT has shown 
promising results for response monitoring during treatment in different human cancers [19], new 
guidelines using 18F-FDG PET/CT have emerged (PERCIST) [20]. Likewise, 18F-FLT has shown 
promising results for early response monitoring in human head and neck cancer [21,22]. Precisely  
the use of these two PET/CT tracers for response monitoring after radiotherapy in canine cancer 
patients was first published in a case report where 18F-FLT PET/CT in supplement to 18F-FDG 
revealed disease recurrence [23]. During the last two years, a couple of interesting canine studies have 
followed. A study of 10 canine patients with sinonasal cancers (seven adenocarcinomas, a 
chondrosarcoma, a osteosarcoma, and a squamous cell carcinoma) used pre-treatment 18F-FDG,  
18F-FLT, and 61Cu-ATSM PET/CT scans and a single 18F-FDG PET/CT scan three months  
post-radiotherapy (50 Gy in 10 fractions) for spatially resolved regression analysis to investigate the 
impact of the pre-treatment scans in predicting the response to radiotherapy [24]. The results revealed 
that the pre-treatment 18F-FDG PET uptake was a significant positive predictor of three-month  
post-treatment 18F-FDG PET uptake, though with histopatological discrepancies, while baseline  
18F-FLT and 61Cu-ATSM PET uptake did not contribute significantly to multivariate regression  
coefficients [24]. This study is, however, limited by the absence of follow-up PET/CT scans with  
18F-FLT and 61Cu-ATSM. Members of the same research group in a later study compared the spatial 
correlation of 18F-FDG, 18F-FLT, and 61Cu-ATSM during PET/CT in a cohort of 22 canine patients 
with sinonasal cancers, eight of which were sarcomas [25]. They found a significantly greater overlap 
between the highest uptake volumes of the three tracers in carcinomas than in sarcomas, a finding 
comparable to the visual interpretations of our PET/CT images in a canine fibrosarcoma. A more 
recent study of the same canine cohort investigating the changes in 18F-FLT and 61Cu-ATSM PET 
uptakes between pre-treatment and mid-treatment PET/CT scans during hypo-fractionated radiotherapy 
showed a significant reduction in the 61Cu-ATSM uptake after three fractions of intensity-modulated 
radiation therapy (IMRT) (12.6 or 15 Gy) in carcinomas, but not in sarcomas [26]. The reduction in 
18F-FLT PET uptake after two fractions of IMRT (8.4 or 10 Gy) was significant for both tumor  
types [26]. Visual interpretation of our PET/CT scan results in Figure 1 show a similar tendency as the 
18F-FLT PET uptake is reduced more than the 64Cu-ATSM PET uptake from pre-treatment to  
mid-treatment, though keeping in mind that our mid-treatment scan is first performed after 22.5 Gy 
and the 64Cu-ATSM scan is performed approximately 6.5 h after injection and not 3 h, as Bradshaw et al. 
used in their study [26]. A recent study of changes in dynamic 18F-FDG PET/CT and  
contrast-enhanced cone beam CT between pre-, mid-, and post-treatment scans during IMRT  
(40–46 Gy in 10 fractions) of three canine patients with spontaneous head and neck tumors illustrated 
the attractiveness of doing multi-modal, multi-parameter imaging for evaluating therapy-induced 
tumor modifications [27]. This study, however, like ours, only included a very limited number of 
patients. Therefore, further studies are necessary before the incorporation of multiple expensive PET 
tracers in routine treatment response monitoring might become a reality. 
Taken together, our pilot study has presented unique data regarding the simultaneous use of 
multiple tracers for response monitoring. Using more than one tracer reveals potentially important 
information about tumor heterogeneity. It is apparent from our study as well as the other studies 
discussed that different tracers contribute distinctive information about the tumor phenotype, 
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information that may differ between different histopatologic cancer types, as the studies by  
Bradshaw et al. showed [25,26]. Furthermore, being markers of different molecular pathways within the 
tumor cells and their microenvironment, the individual tracers respond diversely to treatment, as seen in 
our study. Thus, each tracer adds unique information when using more than one tracer for response 
monitoring. Further investigations including more canine patients are, however, necessary to elucidate 
the true value and benefits of using a combination of 18F-FDG, 18F-FLT, and 64Cu-ATSM PET/CT 
when monitoring response during radiotherapy and to verify the exact significance of using these tracers 
for individualized treatment planning. Another important aspect to consider is how to interpret the sum 
of information gained through multi-tracer imaging, and also further study which scan time points are 
most relevant for response evaluation and prediction of outcome. 
Since the biological features of canine cancers resemble human cancers and similar therapies are used 
for solid tumors in dog and man, further canine studies evaluating multi-tracer PET/CT for therapy 
planning and response monitoring may give valuable information for both canine and human patients. 
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